Published in Pharmazie on April 01, 1990
Ultrafast spin transport as key to femtosecond demagnetization. Nat Mater (2013) 2.60
Femtosecond modification of electron localization and transfer of angular momentum in nickel. Nat Mater (2007) 2.57
Femtosecond undulator radiation from sliced electron bunches. Phys Rev Lett (2006) 1.49
Annual night visiting rates in 129 general practices in one family health services authority: association with patient and general practice characteristics. Br J Gen Pract (1995) 1.43
Minimal incision abdominal aortic aneurysm repair. J Vasc Surg (1999) 1.42
[Alcohol as an agent against coronary heart disease-- flippancy or fact?]. Tidsskr Nor Laegeforen (1997) 1.39
Specific developmental gene silencing in the honey bee using a homeobox motif. Insect Mol Biol (2002) 1.32
Cellular uptake of an alpha-helical amphipathic model peptide with the potential to deliver polar compounds into the cell interior non-endocytically. Biochim Biophys Acta (1998) 1.23
Characterization of cell volume loss in CEM-C7A cells during dexamethasone-induced apoptosis. Am J Physiol (1996) 1.15
Centralization of low back pain and perceived functional outcome. J Orthop Sports Phys Ther (1998) 1.04
Ht31: the first protein kinase A anchoring protein to integrate protein kinase A and Rho signaling. FEBS Lett (2001) 0.94
Percutaneous angioplasty for peripheral arterial occlusive disease. Correlates of clinical success. Arch Surg (1987) 0.93
Genetic epidemiology of BRCA1 mutations in Norway. Eur J Cancer (2001) 0.92
Biomedical and pharmaceutical applications of alginate and chitosan. Biotechnol Genet Eng Rev (1999) 0.91
Differential induction of etoposide-mediated apoptosis in human leukemia HL-60 and K562 cells. Mol Pharmacol (1994) 0.88
Further characterisation of the in situ terminal deoxynucleotidyl transferase (TdT) assay for the flow cytometric analysis of apoptosis in drug resistant and drug sensitive leukaemic cells. Cytometry (1995) 0.87
Cell therapy using encapsulated cells producing endostatin. Acta Neurochir Suppl (2003) 0.85
Valsartan, a new angiotensin II antagonist for the treatment of essential hypertension: efficacy and safety compared to hydrochlorothiazide. Eur J Clin Pharmacol (1997) 0.82
[Action of some serum enzymes following whole-body muscle massage. Contribution to the problem of physical therapy in dermatomyositis]. Arch Dermatol Forsch (1971) 0.81
Epignathus: always a simple teratoma? Report of an exceptional case with two additional fetiforme bodies. Ultrasound Obstet Gynecol (2003) 0.80
Cellular uptake of antisense oligonucleotides after complexing or conjugation with cell-penetrating model peptides. Eur J Biochem (2002) 0.80
Loteprednol etabonate: a soft steroid for the treatment of allergic diseases of the airways. Drugs Today (Barc) (2000) 0.79
[Problems in the diagnosis of homicide in newborns]. Z Rechtsmed (1970) 0.78
Loads on muscles, tendons and bones in the hind extremities of sheep--a theoretical study. Anat Histol Embryol (1993) 0.78
The calcium messenger system and the kinetics of elastase release from human neutrophils in patients with abdominal aortic aneurysms. Ann Vasc Surg (1990) 0.78
[Contribution to the atypical macroglia in nonhepatic diseases (author's transl)]. Zentralbl Allg Pathol (1978) 0.78
[The hemodynamic and cardiac effects of toluidine blue on the anesthetized dog]. Pharmazie (1978) 0.78
[The technique of outflow tract reconstruction in patients with tetralogy of Fallot influence the morbidity 3 decades after repair]. Z Kardiol (2004) 0.78
Gastroenterology, diagnosis-related groups, and age. J Clin Gastroenterol (1989) 0.77
Brief depression among patients in general practice. Prevalence and variation by recurrence and severity. Eur Arch Psychiatry Clin Neurosci (1994) 0.76
Responses of normal and rheumatic human articular chondrocytes cultured under various experimental conditions in agarose. Scand J Rheumatol (1991) 0.76
Some observations indicating a low brain uptake of [3H]Nle11-Substance P. Pharmazie (1983) 0.76
Rapid assay for in vitro degradation of luteinizing hormone releasing hormone. Anal Biochem (1982) 0.76
Femtosecond terahertz radiation from femtoslicing at BESSY. Phys Rev Lett (2006) 0.76
[Dying through the hand of man or taken by the hand of man? Results of an opinion poll concerning active euthanasia and the Hospice Movement]. Med Klin (Munich) (1999) 0.75
The potential for aromatase inhibition in breast cancer prevention. Clin Cancer Res (2001) 0.75
[Synthesis and alpha-adrenolytic activities of 2-(1,4-benzodioxan-2-yl- methyl)-6,7-dimethoxy-1,2,3,4-tetrahydroisoquinoline derivatives]. Pharmazie (1990) 0.75
[Synthesis of 3-substituted 6-methyl-4-pyridyl-2 (1H) pyridones and testing of their cardiovascular action]. Pharmazie (1988) 0.75
[Modification of smooth muscle contractility by Cordemcura]. Pharmazie (1986) 0.75
[Spinal epidural hematoma and its etiology]. Zentralbl Chir (1991) 0.75
[A look at American and Canadian hospitals. Same targets--different pathways]. Krankenpfl Soins Infirm (1995) 0.75
[On the cardiovascular and beta-adrenergic blocking effects produced in the beagle dog by repeated oral administration of talinolol (Cordanum) and propranolol (author's transl)]. Pharmazie (1980) 0.75
Ultrafast dynamics of delocalized and localized electrons in carbon nanotubes. Phys Rev Lett (2006) 0.75
[Improved patient monitoring during intracranial pressure measurement by calculating a theoretical pressure-volume curve]. Zentralbl Chir (1992) 0.75
[Pharmacological research on bonnecor and its metabolites]. Farmakol Toksikol (1990) 0.75
[Potential cardiotonic agents. 11. Synthesis and cardiovascular effects of 5-alkyl-substituted 2-amino-3-cyano-5- -4-dyl)pyridines]. Pharmazie (1990) 0.75
Tritium labeling of gonadotropin releasing hormone in its proline and histidine residues. Peptides (1981) 0.75
[Prognostic factors and results of treatment in endometrial carcinoma]. Zentralbl Gynakol (1996) 0.75
[Potential cardiotonic agents. 8. 2-acyloxyalkylamino-, 2-acyloxyalkoxy-, and 2-acylaminoalkylamino-3-cyan-5-(pyrid-4-yl) pyridine]. Pharmazie (1990) 0.75
[On the circulatory pharmacology of the new beta-adrenergic agent dobutamine (author's transl)]. Pharmazie (1980) 0.75
Protection of methionine in peptides during iodination by sulfonium salt formation. Int J Pept Protein Res (1982) 0.75
On the blood-brain barrier to peptides: [3H]gonadotropin-releasing hormone accumulation by eighteen regions of the rat brain and by anterior pituitary. Exp Clin Endocrinol (1984) 0.75
[Pharmacology of 1-phenylaminoethylamino-3-(phenoxy)propanol derivatives with beta-adrenergic action]. Pharmazie (1983) 0.75
Direct tritium-labelling into histidine of luteinizing hormone-releasing hormone agonists and use of the tracers in studies on proteolytic breakdown. Biochim Biophys Acta (1983) 0.75
1,5-Disubstituted indazol-3-ols with anti-inflammatory activity. Arch Pharm (Weinheim) (1998) 0.75
[Antiarrhythmic amidinohydrazone substituted benzophenones. 2. Preparation and determination of configuration of (Z)- and (E)-2-amino-5-chlorobenzophenone amidinohydrazone salts]. Pharmazie (1992) 0.75
[What is your diagnosis? Congenital pulmonary stenosis with signs of a distinct diminishing lung perfusion]. Schweiz Arch Tierheilkd (1995) 0.75
[Extending informative value of intracranial pressure measurement by cerebral pressure amplitudes (Pa)--analysis of average intracranial pressure (Pm)]. Zentralbl Chir (1992) 0.75
Hydrops fetalis caused by a large intrapericardial teratoma. Ultrasound Obstet Gynecol (2006) 0.75
[Sterile, purulent meningitis and generalized vasculitis caused by a new drug for prevention of nidation in the dog]. Schweiz Arch Tierheilkd (1987) 0.75
[Potential cardiotonics. 5. Preparation and properties of 6-unsubstituted and 6-methyl-substituted 3-cyan-5-(pyrid-4-yl)pyridine]. Pharmazie (1989) 0.75
[On the cardiac and hemodynamic side-effects of the beta 2-adrenergic broncholytic agent clenbuterol (Contraspasmin)]. Pharmazie (1982) 0.75
[1st European Conference for caregivers, Copenhagen. The nurses' fear of AIDS]. Krankenpfl Soins Infirm (1990) 0.75
[Potential cardiotonics. 9. Synthesis and cardiovascular effects of 2-(pyrid-3-yl)-methylamino-, 2-(3-amino-pyrazolidino)- and 2-hetarylamino-substituted 3-cyan-5-(pyrid-4-yl)-pyridines]. Pharmazie (1989) 0.75
[Cardiac effects of Cordemcura in vitro]. Pharmazie (1986) 0.75
[Potential cardiotonic agents. 1. Synthesis and pharmacologic properties of 3-cyano-2-oxaalkylamino-5-(4-pyridinyl)pyridines]. Pharmazie (1989) 0.75
[What is your diagnosis? Decompensating dilated cardiomyopathy]. Schweiz Arch Tierheilkd (1993) 0.75
[Linear relations of brain pulse amplitude to mean intracranial pressure]. Zentralbl Neurochir (1992) 0.75
[What is your diagnosis? What measures do you recommend?]. Schweiz Arch Tierheilkd (1986) 0.75
Early diagnosis of conjoined twins by real-time three-dimensional ultrasound--case report and review of the literature. Ultraschall Med (2006) 0.75
[Spectrum of the adverse effects of Cordemcura]. Pharmazie (1986) 0.75
[Synthesis and pharmacologic properties of pranolium and its optical isomers]. Pharmazie (1990) 0.75
[Potential cardiotonic agents. 2. Synthesis and pharmacologic properties of 5-(pyri-4-yl)- and 5-phenyl substituted 3-cyano-6-methyl-2-oxaalkylaminopyridines]. Pharmazie (1989) 0.75
Reproductive outcomes in women exposed to solvents in 36 reinforced plastics companies. I. Menstrual dysfunction. J Occup Med (1985) 0.75
Echocardiographic diagnosis of a cardiac fibrosarcoma in the right atrium of a sheep. Schweiz Arch Tierheilkd (1995) 0.75
[Anti-arrhythmic action of some amidinohydrazone substituted benzophenones. 1. Synthesis of new amidinohydrazone and N-phenylamidinohydrazone substituted benzophenones]. Pharmazie (1992) 0.75
[Acute cerebrovascular disease at the internal medicine hospital]. Z Gesamte Inn Med (1987) 0.75
[Neuroradiologic study of patients with spinal injuries]. Z Arztl Fortbild (Jena) (1986) 0.75
[The spinal emergency. Urgent indications for surgical intervention in spondylogenic lumbar processes]. Z Arztl Fortbild (Jena) (1989) 0.75
[Potential cardiotonic agents. 4. Synthesis, cardiovascular activity, molecular and crystal structure of 5-phenyl- and 4-(4-pyridinyl)-substituted 2(1H)-pyridinethiones]. Pharmazie (1989) 0.75
[ECG abnormalities in Airedale terriers]. Tierarztl Prax (1996) 0.75
Optical dimer excitations and exchange parameters in (Et4N)3Cr2F9: first observation of the 4A2 --> 2A1 transition. Inorg Chem (2001) 0.75
[Ultrasonic tomography--a noninvasive, imaging study method in lumbar canal diagnosis]. Radiol Diagn (Berl) (1988) 0.75
[Potential cardiotonic agents. 6. Synthesis and cardiovascular properties of 5-(4-pyridinyl)-, 6-methyl-5-(4-pyridinyl)- and 6-methyl-5-phenyl-substituted 3-cyano-2-oxaalkyoxy-pyridines]. Pharmazie (1990) 0.75
[Potential cardiotonic agents. 10. Synthesis and positive inotropic action of 5-(4-pyridinyl)- and 5-phenyl-substituted 2-alkylthio-3-cyan-pyridines and their S-oxidation products]. Pharmazie (1990) 0.75
Protection by antiarrhythmic drugs against ischemia-induced arrhythmias occurring during coronary artery occlusion in the rat. Biomed Biochim Acta (1987) 0.75
[Incidence of abnormalities following the use of hormonal contraceptives]. Zentralbl Gynakol (1989) 0.75
[A personal milk bank in the State Hospital]. Jordmorbladet (1997) 0.75
[Potential cardiotonics. 14. Synthesis and in vitro positive inotropic actions of 4-morpholino-5-(4-pyridinyl)pyridine derivatives]. Pharmazie (1992) 0.75
[What is your diagnosis? Pulmonary edema following changes in capillary permeability due to acute respiratory distress syndrome]. Schweiz Arch Tierheilkd (1997) 0.75